News

Two companies are seeking approval for a Composite Scheme of Amalgamation, with one company to be absorbed into the other. The National Company Law Tribunal (NCLT) has dispensed with the need for meetings for shareholders and creditors of both entities, but a meeting is required for shareholders of the Transferee Company on October 24, 2026, at the company’s registered office in Hyderabad, accessible via video conferencing. Ms. Sarvani Desiraju will chair the meeting, with Ms. Kruthi Kalaga serving as the scrutinizer, receiving remuneration of Rs 1,50,000 and Rs 75,000 respectively. Shareholders of the Transferee Company will receive notice 30 days prior, and a share exchange ratio of one share for one share will be implemented, with new shares carrying equivalent rights.

Venmax Drugs & Pharmaceuticals Limited will hold a board meeting on August 31, 2026, at 4:30 P.M. to discuss the notice, directors` report, and annual report for the financial year 2025-26, as well as to decide on the date, time, and venue of the 37th Annual General Meeting.

Net profit of Venmax Drugs & Pharmaceuticals rose 200.00% to Rs 0.12 crore in the quarter ended June 2026 as against Rs 0.04 crore during the previous quarter ended June 2025. Sales rose 104.96% to Rs 2.48 crore in the quarter ended June 2026 as against Rs 1.21 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales2.481.21 105 OPM %4.843.31 - PBDT0.120.04 200 PBT0.120.04 200 NP0.120.04 200 Powered by Capital Market - Live News

Venmax Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 7 August 2026.

Net profit of Venmax Drugs & Pharmaceuticals declined 85.90% to Rs 0.11 crore in the quarter ended March 2026 as against Rs 0.78 crore during the previous quarter ended March 2025. Sales rose 1093.94% to Rs 3.94 crore in the quarter ended March 2026 as against Rs 0.33 crore during the previous quarter ended March 2025.For the full year,net profit reported to Rs 0.25 crore in the year ended March 2026 as against net loss of Rs 0.01 crore during the previous year ended March 2025. Sales rose 890.12% to Rs 8.02 crore in the year ended March 2026 as against Rs 0.81 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales3.940.33 1094 8.020.81 890 OPM %0.51-72.73 -1.50-129.63 - PBDT0.110.78 -86 0.280 0 PBT0.110.78 -86 0.28-0.01 LP NP0.110.78 -86 0.25-0.01 LP Powered by Capital Market - Live News